Contact Dermatitis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CNT047 MIFTS: 55	Contact Dermatitis Categories: Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Contact Dermatitis

MalaCards integrated aliases for Contact Dermatitis:

Name: Contact Dermatitis ¹¹ ⁷⁵ ¹⁴ ¹⁶ ⁷¹

Contact Dermatitis/eczema ¹¹

Dermatitis, Venenata ¹¹

Dermatitis Venenata ¹¹

Dermatitis, Contact ⁴³

Dermatitis Contact ⁵³

Contact Eczema ¹¹

Classifications:

MalaCards categories:
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the skin and subcutaneous tissue

Dermatitis and eczema

Unspecified contact dermatitis

Unspecified contact dermatitis due to cosmetics

Unspecified contact dermatitis due to drugs in contact with skin

Unspecified contact dermatitis due to dyes

Unspecified contact dermatitis due to food in contact with skin

Unspecified contact dermatitis due to other agents

Unspecified contact dermatitis due to other chemical products

Unspecified contact dermatitis due to plants, except food

Unspecified contact dermatitis, unspecified cause

External Ids:

Disease Ontology ¹¹ DOID:2773

MeSH ⁴³ D003877

NCIt ⁴⁹ C26743

SNOMED-CT ⁶⁸ 156338009

ICD10 ³¹ L25 L25.0 L25.1 more

EFO ¹⁶ EFO_0005319

UMLS ⁷¹ C0011616

Sources

Summaries for Contact Dermatitis

MalaCards based summary: Contact Dermatitis, also known as contact dermatitis/eczema, is related to irritant dermatitis and nickel allergic contact dermatitis, and has symptoms including pruritus and exanthema. An important gene associated with Contact Dermatitis is IL31 (Interleukin 31), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Triamcinolone and Clobetasol have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and lymph node, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia: ⁷⁵ Contact dermatitis is a type of acute or chronic inflammation of the skin caused by exposure to chemical... more...

Sources

Related Diseases for Contact Dermatitis

Diseases related to Contact Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 871)

#	Related Disease	Score	Top Affiliating Genes
1	irritant dermatitis	33.2	TSLP TNF KRT16 IL4 IL31 IL1B
2	nickel allergic contact dermatitis	33.1	IL5 IL13
3	palladium allergic contact dermatitis	33.0	TNF IL1B
4	allergic contact dermatitis	33.0	TSLP TNF IL5 IL4 IL31 IL1B
5	chromium allergic contact dermatitis	33.0	IL5 IL4 IL13
6	photoallergic dermatitis	33.0	FLG CCR6
7	occupational dermatitis	32.9	IL31 FLG
8	dermatitis	32.4	TSLP TNF KRT16 IL5 IL4 IL31
9	metal allergy	32.3	TNF IL5 IL4 IL1B IL13 FLG
10	cercarial dermatitis	31.9	IL5 IL4
11	dermatitis, atopic	31.8	TSLP TNF IL5 IL4 IL31 IL1B
12	ige responsiveness, atopic	31.8	IL5 IL4 IL13 IFNG
13	urticaria	31.7	TSLP TNF IL5 IL4 IL31 IL1B
14	exanthem	31.7	TNF IL4 IL1B IFNG ICOSLG CCR6
15	erythema multiforme	31.6	TNF IL5 IL4 IL1B IL13 IFNG
16	allergic disease	31.4	TSLP TNF IL5 IL4 IL1B IL13
17	chronic rhinitis	31.4	IL5 IL4 IL13
18	alopecia	31.4	TNF IL4 IL1B IL1A IFNG FLG
19	skin disease	31.3	TSLP TNF KRT17 KRT16 IL5 IL4
20	acne	31.3	TNF IL1RN IL1B IL1A FLG
21	seborrheic dermatitis	31.3	TNF IL1A FLG CCR6
22	dermatophytosis	31.3	TNF IL1B CCR6
23	conjunctivitis	31.2	TNF IL5 IL4 IL13 IFNG CXCL9
24	vitiligo-associated multiple autoimmune disease susceptibility 1	31.1	TNF ICOSLG CCR6
25	allergic rhinitis	31.1	IL5 IL4 IL13 IFNG
26	lichen planus	31.1	TNF KRT16 IL4 IL1B IFNG FLG
27	occupational asthma	31.1	TSLP IL5 IL4 IL13
28	stomatitis	31.1	TNF IL4 IL1B IFNG
29	rhinitis	31.1	TSLP TNF IL5 IL4 IL1B IL13
30	drug allergy	31.0	IL5 IL4 IL13
31	severe cutaneous adverse reaction	31.0	TNF IFNG CCR6
32	purpura	31.0	TNF IL4 IL1B IFNG
33	pulpitis	31.0	TNF IL1B IL1A
34	pustular psoriasis	30.9	TNF IFNG CXCL9 CXCL10
35	proteasome-associated autoinflammatory syndrome 1	30.9	TNF IL5 IL4 IL1RN IL1B IL1A
36	fungal infectious disease	30.9	TNF IL5 IL4 IL1B IL1A IL13
37	allergic asthma	30.9	TSLP IL5 IL4 IL13 IFNG CCR6
38	cellulitis	30.9	TNF IL5 IL1B CCR6
39	folliculitis	30.9	TNF IL5 IL4 IFNG CCR6
40	mycosis fungoides	30.8	IL5 IL4 IFNG CXCR3 CXCL9 CXCL10
41	psoriasis	30.8	TNF KRT17 KRT16 IL5 IL4 IL31
42	primary cutaneous t-cell non-hodgkin lymphoma	30.8	IL5 IL4 IFNG CXCR3 CXCL10 CCR6
43	pemphigoid	30.8	TNF IL5 IL4 IL31 IL1B IL13
44	scabies	30.8	IL5 IL4 IL31 IL13 FLG CCR6
45	covid-19	30.8	TNF IL4 IL1B CXCL10 CCR6
46	skin atrophy	30.8	TNF IL4 IL31 FLG
47	hypereosinophilic syndrome	30.8	IL5 IL4 IL13 IFNG
48	food allergy	30.7	TSLP TNF IL5 IL4 IL13 IFNG
49	type 1 diabetes mellitus	30.7	TNF IL4 IL1B IFNG ICOSLG CXCL10
50	pyoderma	30.7	TNF IL1B CCR6

Graphical network of the top 20 diseases related to Contact Dermatitis:

Sources

Symptoms & Phenotypes for Contact Dermatitis

UMLS symptoms related to Contact Dermatitis:

pruritus; exanthema

MGI Mouse Phenotypes related to Contact Dermatitis:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.27	CCR6 CXCL10 CXCL9 CXCR3 ICOSLG IFNG
2	immune system	MP:0005387	10.16	CCL22 CCR4 CCR6 CXCL10 CXCL9 CXCR3
3	digestive/alimentary	MP:0005381	9.92	IFNG IL13 IL4 IL5 KRT16 KRT17
4	hematopoietic system	MP:0005397	9.86	CCR4 CCR6 CXCL10 CXCL9 CXCR3 ICOSLG
5	respiratory system	MP:0005388	9.76	CCR4 CXCR3 IFNG IL13 IL4 IL5
6	integument	MP:0010771	9.32	IFNG IL13 IL1A IL1B IL1RN IL4

Sources

Drugs & Therapeutics for Contact Dermatitis

Drugs for Contact Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Triamcinolone

Approved, Vet_approved

Phase 4

124-94-7

31307

Clobetasol

Approved, Experimental, Investigational

Phase 4

25122-46-7, 25122-41-2

2791 5311051 32798

Glycerin

Approved, Investigational

Phase 4

56-81-5

753

Mineral oil

Approved, Vet_approved

Phase 4

8042-47-5

Povidone K30

Approved, Experimental, Withdrawn

Phase 4

9003-39-8

6917 131751496

Tacrolimus

Approved, Investigational

Phase 4

104987-11-3

6473866 445643

Triamcinolone hexacetonide

Phase 4

Triamcinolone diacetate

Phase 4

Triamcinolone Acetonide

Phase 4

6436

Emollients

Phase 4

Immunosuppressive Agents

Phase 4

Immunologic Factors

Phase 4

Calcineurin Inhibitors

Phase 4

Afamelanotide

Approved, Investigational

Phase 3

75921-69-6

16132954 16197727

Petrolatum

Approved, Investigational

Phase 2, Phase 3

8009-03-8

Fluticasone

Approved, Experimental

Phase 2, Phase 3

90566-53-3

4659387 5311101

Betamethasone

Approved, Vet_approved

Phase 2, Phase 3

378-44-9

9782

Adalimumab

Approved, Experimental

Phase 2, Phase 3

331731-18-1

Ustekinumab

Approved, Investigational

Phase 2, Phase 3

815610-63-0

Coconut

Approved

Phase 3

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 3

67-97-0, 1406-16-2

5280795 10883523

Squaric acid dibutyl ester

Investigational

Phase 2, Phase 3

2892-62-8

Bronchodilator Agents

Phase 2, Phase 3

Anti-Asthmatic Agents

Phase 2, Phase 3

Adjuvants, Immunologic

Phase 2, Phase 3

Betamethasone-17,21-dipropionate

Phase 2, Phase 3

Betamethasone Valerate

Phase 2, Phase 3

2152-44-5

Betamethasone sodium phosphate

Phase 2, Phase 3

Betamethasone benzoate

Phase 2, Phase 3

Anti-Allergic Agents

Phase 2, Phase 3

Xhance

Phase 2, Phase 3

Anesthetics, Local

Phase 2, Phase 3

Anesthetics

Phase 2, Phase 3

Respiratory System Agents

Phase 2, Phase 3

Analgesics

Phase 2, Phase 3

Antirheumatic Agents

Phase 3

Interleukin 1 Receptor Antagonist Protein

Phase 3

Hormones

Phase 3

Trace Elements

Phase 3

Micronutrients

Phase 3

Vitamins

Phase 3

Calciferol

Phase 3

Calcium, Dietary

Phase 3

Calcium

Nutraceutical

Phase 3

7440-70-2

271

Apremilast

Approved, Investigational

Phase 2

608141-41-9

10151715 11561674

Thalidomide

Approved, Investigational, Withdrawn

Phase 2

50-35-1

5426

Mechlorethamine

Approved, Investigational

Phase 2

51-75-2

4033

Anti-Bacterial Agents

Phase 2

Phosphodiesterase Inhibitors

Phase 2

Phosphodiesterase 4 Inhibitors

Phase 2

Interventional clinical trials:

(show top 50) (show all 81)

#	Name	Status	NCT ID	Phase	Drugs
1	An Open Single Centre Evaluation of the Reactivity of the T.R.U.E. Test Quaternium-15 Patch and a Real Use Exposure in Subjects Known to Be Allergic to Quaternium-15	Unknown status	NCT00311454	Phase 4	T.R.U.E.Test
2	Comparison of Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Experimentally Induced Skin Irritation	Unknown status	NCT00779792	Phase 4	clobetasol;triamcinolone acetonide;tacrolimus;glycerol;vehicle ointment (paraffin oil/soft white paraffin)
3	Clinical Evaluation of TRUE Test Ethylenediamine Dihydrochloride Allergen: Bioequivalence of Vehicle Formulations	Completed	NCT01798589	Phase 4	Ethylenediamine dihydrochloride allergen patch
4	A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Trial to Assess the Safety and Efficacy of 0.1% Tacrolimus Ointment in the Treatment of Chronic Allergic Contact Dermatitis	Completed	NCT00667056	Phase 4	tacrolimus ointment;placebo ointment
5	Clinical Evaluation of T.R.U.E. TEST® Panel 1.1, 2.1 and 3.1: in Children and Adolescents	Completed	NCT00795951	Phase 4
6	The Effects of Dupilumab on Allergic Contact Dermatitis	Recruiting	NCT03935971	Phase 4	Dupilumab
7	Comparative Evaluation of the Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in the Treatment of Pediatric and Adult Dermatosis	Unknown status	NCT01011621	Phase 3	0.5% prednisolone acetate cream;0.1% betamethasone valerate cream
8	Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Gold Sodium Thiosulfate, Hydrocortisone-17-Butyrate, Methyldibromoglutaronitrile, Bacitracin, Parthenolide, Disperse Blue 106, and Bronopol	Completed	NCT00640614	Phase 3
9	A Phase III, Randomised, Double Blind, Placebo Controlled, Parallel Group Study, to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide (16 mg) in Patients Suffering From Polymorphic Light Eruption (PLE)	Completed	NCT04704713	Phase 3	Afamelanotide;Placebo
10	Biologics and Blistering - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Through Suction Blistering	Recruiting	NCT05535738	Phase 2, Phase 3	Squaric Acid Dibutyl Ester;Dupilumab;Adalimumab;Ustekinumab;Guselkumab;Canakinumab;Sarilumab;Triamcinolone Acetonide;Betamethasone Valerate;Fluticasone Propionate
11	Comparing Tissue Adhesives in Port Site Closure: A Randomized Controlled Trial	Recruiting	NCT05492721	Phase 3
12	The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis: A Randomized Controlled Trial With Anakinra vs. Placebo	Not yet recruiting	NCT05498467	Phase 3	Anakinra;Sodium Chloride 9mg/ml Injection
13	Vitamin D3 Supplementation in Polymorphic Light Eruption: Randomized Double-blinded Placebo-controlled Trial	Terminated	NCT01595893	Phase 3	Oral Vitamin D 3;Miglyol 812 N
14	Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents	Withdrawn	NCT01518348	Phase 3
15	Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study	Completed	NCT02028208	Phase 2
16	Clinical Evaluation of Hydroxyisohexyl 3-cyclohexene Carboxaldehyde (Lyral®) Dose Response Study	Completed	NCT02028182	Phase 2
17	Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Bronopol and Disperse Blue 106 Dose Response Study	Completed	NCT00640250	Phase 2
18	A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of Three Weeks of Daily Dermal Application of MRX-6 (2% HyPE) on the Treatment of Mild to Moderate Contact Dermatitis of the Hand and Forearm	Completed	NCT00867607	Phase 1, Phase 2	MRX-6;Steroid
19	A Phase 2, Open-label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Contact or Atopic Dermatitis	Completed	NCT00931242	Phase 2	Apremilast
20	Clinical Evaluation of Bacitracin. A Phase II Dose-Response Study	Completed	NCT00132600	Phase 2	bacitracin (allergen)
21	Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate for "TRUE Test® Panel 3" - a Phase II, Dose-Response Study.	Completed	NCT00133341	Phase 2	Goldnatriomthiosulphate, MDBGN, parthenolide
22	Valchlor Therapy in Conjunction With Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Patients With Early Stage Cutaneous T-cell Lymphoma (Mechlorethamine Induced Dermatitis Avoidance Study)	Completed	NCT03380026	Phase 2	Triamcinolone;Valchlor 0.016 % Topical Gel
23	A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis	Completed	NCT00928447	Phase 2	rHuPH20;Placebo
24	Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens: Bioequivalence of Polyvinylpyrrolidone (PVP) Formulations	Completed	NCT00612768	Phase 2
25	A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects With Chronic Allergic Contact Dermatitis	Active, not recruiting	NCT03680131	Phase 2	EB01 Cream Placebo;EB01 Cream 0.2%;EB01 Cream 1.0%;EB01 Cream 2.0%
26	A Phase I, Single-Center, Double-Blind, Randomized, Single Ascending Dose Study of PDC-APB in Healthy Volunteers	Completed	NCT02700373	Phase 1	PDC-APB;Placebo
27	A Randomized, Controlled Study to Evaluate the Effect of Topically Applied BBI-2000 (5%) on Allergic Responses in Subjects With Contact Hypersensitivity to Diphencyprone	Completed	NCT03089775	Phase 1	BBI-2000;Vehicle
28	Phase 1 Study to Demonstrate Efficacy of Epikeia Coatings in a Human Clinical Trial	Completed	NCT00614289	Phase 1
29	A Proof-of-Principle Study Investigating the Effect of Single Doses of NI-0801 on Nickel Induced Contact Dermatitis	Completed	NCT01244607	Phase 1	Placebo;NI-0801
30	A Single-Site Study To Evaluate the Sensitization Potential of Topically Applied ATx201 in Healthy Human Volunteers	Completed	NCT03375957	Phase 1	ATx201;ATx201 Placebo Gel
31	Pilot, Phase I, Single Blind Trial to Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers. (PRURITUS- Nimpa Study).	Completed	NCT01529320	Phase 1	Adventan® (methylprednisolone aceponate 0,1%)
32	A Phase I, Single-Center, Double-Blind, Randomized Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB in Healthy Volunteers With a History of Contact Dermatitis Due to Poison Ivy Exposure	Not yet recruiting	NCT04853823	Phase 1	PDC-APB
33	Bariederm Cream in Chronic Contact Dermatitis	Unknown status	NCT02026700
34	Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation	Unknown status	NCT00445029
35	Nickel Desensitization Using Topical Therapy	Unknown status	NCT01413477		Calcipotriol, Betamethasone, Calcipotriol & Betamethasone
36	The Use of Coconut Oil for the Prevention and Treatment of Diaper Dermatitis in the NICU Population	Unknown status	NCT02614248
37	Medrol® In Contact Dermatitis: A Prospective Study To Assess The Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Subjects	Completed	NCT00929981		Tablet Methylprednisolone (4 or 16 mg)
38	Low Dose Exposure to Oxidized R-limonene - A Double Blinded Vehicle Controlled Repeated Open Application Test (ROAT) Study	Completed	NCT03313232
39	Evaluation of the Clinical Implication of Short Repeated Nickel Exposures	Completed	NCT03309215
40	Exploratory Study of Natural Killer Cells in Human Skin	Completed	NCT00824889
41	Specific Factors Associated With the Development of Incontinence- Associated Dermatitis (IAD) in ICU Patients Suffering From Fecal Incontinence: Matched Case Control Study	Completed	NCT02996357
42	An Open Label Study of the Therapeutic Effects of Tetrix Cream in Allergic Contact and Irritant Contact Dermatitis	Completed	NCT00646867
43	Histopathological Comparison Between Superficial Pressure Ulcers and Incontinence-associated Dermatitis	Completed	NCT03685929
44	Alteration of the microRNA-126 Expression: a Possible Mechanism in Allergic Contact Dermatitis to Nickel	Completed	NCT04365140
45	Comparison of the Effectiveness and Safety Between Moisturizing Cream Containing Niacinamide 4% and Virgin Coconut Oil 30% for Secondary Prevention of Occupational Hand Hermatitis in Intensive Care Unit Nurses: a Double Blind Randomized Clinical Trial	Completed	NCT04218500
46	Oral Human Administration of Red Grape Polyphenol in Nickel-mediated Allergic Contact Dermatitis: an in Vitro Study	Completed	NCT03902392
47	Epidemiology and Co-Reactivity of Novel Surfactant Allergens	Completed	NCT02534441
48	Regional Differences of Cutaneous Irritation and Its Effect on Skin Barrier Recovery: A Randomised, Controlled Trial	Completed	NCT03231813
49	Children With Aluminium Contact Allergy: Cutaneous Exposure Study	Completed	NCT04438135
50	Molecular and Cellular Characterization of Spongiotic Dermatitis	Completed	NCT00371163

Search NIH Clinical Center for Contact Dermatitis

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

pramoxine

Pramoxine hydrochloride

Cochrane evidence based reviews: dermatitis, contact

Sources

Genetic Tests for Contact Dermatitis

Sources

Anatomical Context for Contact Dermatitis

Organs/tissues related to Contact Dermatitis:

MalaCards : Skin, T Cells, Lymph Node, Eye, Neutrophil, Myeloid, Spinal Cord

Sources

Publications for Contact Dermatitis

Articles related to Contact Dermatitis:

(show top 50) (show all 15032)

#	Title	Authors	PMID	Year
1	Filaggrin mutations may confer susceptibility to chronic hand eczema characterized by combined allergic and irritant contact dermatitis. ⁵³ ⁶²	Molin S...Prinz JC	19538184	2009
2	Loss-of-function polymorphisms in the filaggrin gene are associated with an increased susceptibility to chronic irritant contact dermatitis: a case-control study. ⁵³ ⁶²	de Jongh CM...Kezic S	18637008	2008
3	Protein contact dermatitis: allergens, pathogenesis, and management. ⁵³ ⁶²	Levin C...Warshaw E	18845114	2008
4	Polymorphisms in the interleukin-1 gene influence the stratum corneum interleukin-1 alpha concentration in uninvolved skin of patients with chronic irritant contact dermatitis. ⁵³ ⁶²	de Jongh CM...John SM	18416755	2008
5	Allergies in India: an analysis of 3389 patients attending an allergy clinic in Mumbai, India. ⁵³ ⁶²	Shaikh WA...Shaikh SW	18828339	2008
6	Allergic contact dermatitis from natural rubber latex in atopic dermatitis and the risk of later Type I allergy. ⁵³ ⁶²	Guillet G...Dagregorio G	15982232	2005
7	Establishment of an atopic dermatitis-like skin model in a hairless mouse by repeated elicitation of contact hypersensitivity that enables to conduct functional analyses of the stratum corneum with various non-invasive biophysical instruments. ⁵³ ⁶²	Matsumoto K...Tagami H	15059180	2004
8	Expression of CS-1 fibronectin precedes monocyte chemoattractant protein-1 production during elicitation of allergic contact dermatitis. ⁵³ ⁶²	Martin AP...Serra HM	12911787	2003
9	Nickel-induced cytokine production from mononuclear cells in nickel-sensitive individuals and controls. Cytokine profiles in nickel-sensitive individuals with nickel allergy-related hand eczema before and after nickel challenge. ⁵³ ⁶²	Borg L...Poulsen LK	10929769	2000
10	Ultraviolet-B exposure of human skin induces cytochromes P450 1A1 and 1B1. ⁵³ ⁶²	Katiyar SK...Mukhtar H	10651994	2000
11	The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. ⁵³ ⁶²	Flier J...Tensen CP	10504443	1999
12	Chromium induced contact dermatitis and indices for diagnosis. ⁵³ ⁶²	Khalil S...Moussa EM	17219860	1999
13	Keratin 17 is expressed during the course of SLS-induced irritant contact dermatitis, but unlike keratin 16, the degree of expression is unrelated to the density of dividing keratinocytes. ⁵³ ⁶²	Willis CM...Wilkinson JD	9686973	1998
14	In vivo cytokine profiles in allergic and irritant contact dermatitis. ⁵³ ⁶²	Hoefakker S...Claassen E	8654078	1995
15	Cell-bound IgE and increased expression of Fc epsilon-receptors on dendritic cells in cutaneous infiltrates of mycosis fungoides. ⁵³ ⁶²	Preesman AH...van Vloten WA	1834378	1991
16	Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types. ⁶²	Bosma AL...TREAT NL registry and UK-Irish A-STAR Study Groups	36387062	2023
17	Management of Allergic Skin Disorders in Pregnancy. ⁶²	Pope EM...Beck LA	36410998	2023
18	Proteolytic activity accelerates the TH17/TH22 recall response to an epicutaneous protein allergen-induced TH2 response. ⁶²	Ogasawara A...Sakaguchi H	35378053	2022
19	Hydroquinone Induced Skin Irritant Reaction Could Be Achieved by Activating Mast Cells via Mas-related G protein-coupled receptor X2. ⁶²	Zheng Y...Geng S	36463492	2022
20	Cheilitis caused by allergic contact dermatitis to cinnamon in chai tea: a case report. ⁶²	Patel K...Tate B	36461791	2022
21	Severe symptomatic nickel allergy following stent graft implantation requiring excision and external iliac artery reconstruction. ⁶²	Patel R...Jimenez JC	36248398	2022
22	Occupational dermatoses: knowledge, attitudes and perceptions among motor vehicle repair workers. ⁶²	Ahmed AS...Eldahshan RM	34340635	2022
23	Occupational allergic contact dermatitis caused by colophonium, an unsuspected sensitizer in a petrochemical worker. ⁶²	Hamwi S...Tetart F	36050864	2022
24	Allergic contact dermatitis from resacetophenone (2',4'-dihydroxyacetophenone; CAS no. 89-84-9) in an antifungal nail preparation. ⁶²	Pastor-Nieto MA...Gatica-Ortega ME	35980321	2022
25	Alopecia areata after severe allergic contact dermatitis to a permanent hair dye. ⁶²	Gatica-Ortega ME...Pastor-Nieto MA	35984243	2022
26	Occupational airborne allergic contact dermatitis to invasive Compositae species treated with abrocitinib: A case report. ⁶²	Baltazar D...Hamann CR	35980345	2022
27	T cells in resolved allergic contact dermatitis steer tissue inflammation and MMP-12-driven tissue modulation. ⁶²	Gallais Serezal I...Eidsmo L	35984563	2022
28	A cross-sectional study of contact allergens in feminine hygiene wipes: a possible cause of vulvar contact dermatitis. ⁶²	Newton J...Silence C	36448019	2022
29	A case of generalized allergic contact dermatitis due to sodium lauroyl methylaminopropionate in a shampoo. ⁶²	Hirose A...Morizane S	36042564	2022
30	Contact dermatitis to undergarments. ⁶²	Ahuja R...Verma K	36458656	2022
31	Airborne contact dermatitis to epoxy resin for creating herbarium. ⁶²	Yamamoto S...Nakada T	36461679	2022
32	Contact Dermatitis From Amplified Hand Hygiene Practices in the COVID-19 Pandemic Among Medical Students: Frequency, Knowledge, and Attitude. ⁶²	Batool Mutar M	36473521	2022
33	A systematic review of allergic and irritative contact dermatitis of the vulva: the most important allergens/irritants and the role of patch testing. ⁶²	Vandeweege S...Verstraelen H	36458568	2022
34	Protease- and cell type-specific activation of protease-activated receptor 2 in cutaneous inflammation. ⁶²	Fleischer MI...Steinbrink K	36161697	2022
35	Reevaluating Corticosteroid Classification Models in Patient Patch Testing. ⁶²	Chen JY...Yang YW	36169950	2022
36	Results of the patch tests with European baseline series in children: Five years of experience from a single center in Turkey and a review of the literature. ⁶²	Kaksi SA...Ozen T	36437575	2022
37	Review of aluminum, paraben, and sulfate product disclaimers on personal care products. ⁶²	Liszewski W...Scheman A	34144080	2022
38	Formaldehyde Release From Eyelash Glues: Analysis Using the Chromotropic Acid Method. ⁶²	Xiong M...Hylwa S	35674514	2022
39	Patch testing with the European baseline series and 10 added allergens: Single-centre study of 748 patients. ⁶²	Bizjak M...Dinevski D	35736503	2022
40	Quantitative risk assessment of allergens leaching from menstrual hygiene products. ⁶²	Marcelis Q...Vanhaecke T	36067853	2022
41	Systematic Review of Systemic Corticosteroid Effects on Patch Testing. ⁶²	Kim-Lim P...Wu PA	36255380	2022
42	Adverse reactions to cosmetics reported to the Chongqing adverse drug reaction monitoring centre system in China. ⁶²	Wang S...Diao Q	36385252	2022
43	The role of topical capsaicin gel in pain management during microfocused ultrasound treatment for neck laxity. ⁶²	Vachiramon V...Fabi S	36382669	2022
44	Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019-2021 epidemiological situation. ⁶²	Hernandez Fernandez CP...Garcia Doval I	36403138	2022
45	Allergic contact dermatitis from vitamins: A systematic review. ⁶²	Foti C...Barbaud A	36210883	2022
46	Non-occupational allergic contact dermatitis from epoxy resin in children's games. ⁶²	Coco-Viloin M...Giordano-Labadie F	36444522	2022
47	Topical eye medications causing allergic contact dermatitis. ⁶²	Ahlstrom MG...Johansen JD	36382619	2022
48	Too Much of a Good Thing? Allergic Contact Dermatitis to Pimecrolimus. ⁶²	Xiong M...Hylwa S	35318979	2022
49	Allergic contact dermatitis due to excipients in topical drugs. ⁶²	De Marco A...Foti C	36331181	2022
50	Pustular Allergic Contact Dermatitis Caused by a Topical Probiotic. ⁶²	Salah NB...Zili J	36399531	2022

Sources

Genes for Contact Dermatitis

Genes related to Contact Dermatitis (0 elite genes):

(show top 50) (show all 53)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	IL31	Interleukin 31	Protein Coding	24.79	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
2	FLG	Filaggrin	Protein Coding	23.68	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19538184 18637008
3	IL5	Interleukin 5	Protein Coding	20.77	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10929769
4	KRT16	Keratin 16	Protein Coding	18.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9686973
5	IL1A	Interleukin 1 Alpha	Protein Coding	18.16	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18416755 8654078
6	CXCR3	C-X-C Motif Chemokine Receptor 3	Protein Coding	17.59	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10504443 12911787
7	TNF	Tumor Necrosis Factor	Protein Coding	16.28	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	IL1B	Interleukin 1 Beta	Protein Coding	15.6	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	CCL22	C-C Motif Chemokine Ligand 22	Protein Coding	14.93	DISEASES inferred ¹⁴ GeneCards inferred via : Expressions (show sections)
10	IFNG	Interferon Gamma	Protein Coding	14.69	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	CCR4	C-C Motif Chemokine Receptor 4	Protein Coding	13.91	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12911787
12	CXCL10	C-X-C Motif Chemokine Ligand 10	Protein Coding	13.6	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	13.13	DISEASES inferred ¹⁴ ¹⁴
14	IL1RN	Interleukin 1 Receptor Antagonist	Protein Coding	12.9	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	KRT17	Keratin 17	Protein Coding	11.79	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	10.7	DISEASES inferred ¹⁴ ¹⁴
17	CXCL9	C-X-C Motif Chemokine Ligand 9	Protein Coding	10.53	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10504443
18	IL4	Interleukin 4	Protein Coding	9.26	DISEASES inferred ¹⁴
19	IL13	Interleukin 13	Protein Coding	9.18	DISEASES inferred ¹⁴
20	TSLP	Thymic Stromal Lymphopoietin	Protein Coding	9.13	DISEASES inferred ¹⁴
21	MIR21	MicroRNA 21	RNA Gene	8.57	DISEASES inferred ¹⁴ ¹⁴
22	MIR155	MicroRNA 155	RNA Gene	8.56	DISEASES inferred ¹⁴ ¹⁴
23	CCL17	C-C Motif Chemokine Ligand 17	Protein Coding	8.52	DISEASES inferred ¹⁴
24	IL33	Interleukin 33	Protein Coding	8.36	DISEASES inferred ¹⁴
25	CD4	CD4 Molecule	Protein Coding	8.35	DISEASES inferred ¹⁴
26	IL17A	Interleukin 17A	Protein Coding	8.3	DISEASES inferred ¹⁴
27	IL10	Interleukin 10	Protein Coding	8.15	DISEASES inferred ¹⁴
28	LORICRIN	Loricrin Cornified Envelope Precursor Protein	Protein Coding	8.08	DISEASES inferred ¹⁴
29	IL6	Interleukin 6	Protein Coding	8	DISEASES inferred ¹⁴
30	ADH5	Alcohol Dehydrogenase 5 (Class III), Chi Polypeptide	Protein Coding	7.95	GeneCards inferred via : Summaries (show sections)
31	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	7.8	DISEASES inferred ¹⁴
32	CD8A	CD8a Molecule	Protein Coding	7.76	DISEASES inferred ¹⁴
33	SPINK5	Serine Peptidase Inhibitor Kazal Type 5	Protein Coding	7.74	DISEASES inferred ¹⁴
34	IVL	Involucrin	Protein Coding	7.66	DISEASES inferred ¹⁴
35	IL2	Interleukin 2	Protein Coding	7.65	DISEASES inferred ¹⁴
36	CCL11	C-C Motif Chemokine Ligand 11	Protein Coding	7.55	DISEASES inferred ¹⁴
37	CAMP	Cathelicidin Antimicrobial Peptide	Protein Coding	7.53	DISEASES inferred ¹⁴
38	IL9	Interleukin 9	Protein Coding	7.5	DISEASES inferred ¹⁴
39	FOXP3	Forkhead Box P3	Protein Coding	7.47	DISEASES inferred ¹⁴
40	RNASE3	Ribonuclease A Family Member 3	Protein Coding	7.46	DISEASES inferred ¹⁴
41	DEFB4A	Defensin Beta 4A	Protein Coding	7.45	DISEASES inferred ¹⁴
42	TAC1	Tachykinin Precursor 1	Protein Coding	7.38	DISEASES inferred ¹⁴
43	MIR142	MicroRNA 142	RNA Gene	7.37	DISEASES inferred ¹⁴ ¹⁴
44	CRLF2	Cytokine Receptor Like Factor 2	Protein Coding	7.34	DISEASES inferred ¹⁴
45	STAT6	Signal Transducer And Activator Of Transcription 6	Protein Coding	7.34	DISEASES inferred ¹⁴
46	IL31RA	Interleukin 31 Receptor A	Protein Coding	7.34	DISEASES inferred ¹⁴
47	PEDS1	Plasmanylethanolamine Desaturase 1	Protein Coding	7.31	DISEASES inferred ¹⁴
48	TLR2	Toll Like Receptor 2	Protein Coding	7.3	DISEASES inferred ¹⁴
49	SERPINA3	Serpin Family A Member 3	Protein Coding	7.28	DISEASES inferred ¹⁴ ¹⁴
50	CSF2	Colony Stimulating Factor 2	Protein Coding	7.28	DISEASES inferred ¹⁴

Sources

Variations for Contact Dermatitis

Sources

Expression for Contact Dermatitis

Search GEO for disease gene expression data for Contact Dermatitis.

Sources

Pathways for Contact Dermatitis

Pathways related to Contact Dermatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 54)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	14.02	TSLP TNF IL5 IL4 IL31 IL1RN
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.87	TNF IL5 IL4 IL1B IL1A IL13
3	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.54	TNF IL5 IL4 IL1B IL1A IL13
4	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.47	CCL22 CCR4 CCR6 CXCL10 CXCL9 CXCR3
5	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.45	TNF IL5 IL4 IL1B IL1A IL13
6	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.32	CCL22 CXCL10 IFNG IL13 IL1A IL1B
7	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.28	TNF IL5 IL4 IL1B IL1A IL13
8	CCR5 Pathway in Macrophages ⁶⁴ Show member pathways Androgen Signaling ⁶⁴ Chemokine Signaling ⁶⁴ Chemokine signaling pathway ⁷⁴	12.89	CXCR3 CXCL9 CXCL10 CCR6 CCR4 CCL22
9	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.84	TNF IL1B IL1A CXCL9 CXCL10
10	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.7	TNF IL5 IL4 IL1B IL1A IL13
11	NF-kappaB Signaling ³	12.63	TNF IL4 IL1RN IL1B IFNG CXCL10
12	Bacterial infections in CF airways ²² Show member pathways Altered glycosylation of MUC1 in tumor microenvironment ⁷⁴ IL-1 beta-dependent CFTR expression ²² IL1-mediated signaling events ⁶¹ Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²² NTHi-Induced Signaling ⁶⁴ Signal transduction through IL1R ⁷⁴	12.52	CXCL10 IFNG IL1A IL1B IL1RN IL4
13	Interleukin-1 family signaling ⁶⁶ Show member pathways Interleukin-1 signaling ⁶⁶ Interleukin-18 signaling ⁶⁶ Interleukin-38 signaling ⁶⁶	12.51	IL4 IL1RN IL1B IL1A IL13
14	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.43	IL5 IL1B IL1A IL13
15	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.31	TNF IL1B IL1A IFNG
16	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	12.24	TNF IL1RN IL1B IL1A IL13
17	Neuroinflammation and glutamatergic signaling ⁷⁴	12.21	TNF IL4 IL1B IL1A IL13 IFNG
18	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.17	TNF IL5 IL4 IFNG
19	Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions ⁶⁵ Show member pathways Chemokine receptors bind chemokines ⁶⁶	12.16	CXCR3 CXCL9 CXCL10 CCR6 CCR4 CCL22
20	Spinal cord injury ⁷⁴	12.1	TNF IL4 IL1B IL1A IFNG CXCL10
21	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	12.06	IL5 IL1B IL1A IL13
22	Interleukin-4 and Interleukin-13 signaling ⁶⁶	12.06	TNF IL4 IL1B IL1A IL13 CCL22
23	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	12.03	TNF IL5 IL4 IFNG
24	Glucocorticoid receptor regulatory network ⁶¹	11.89	KRT17 IL5 IL4 IL13 IFNG
25	Allograft rejection ⁷⁴	11.89	TNF IL5 IL4 IL1B IL1A IL13
26	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.85	IL4 IL1B IFNG
27	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.81	TNF IL4 IFNG ICOSLG
28	Lung fibrosis ⁷⁴	11.8	IL13 IL1B IL4 IL5 TNF
29	Activation of NF-KappaB by PKR ⁶⁴ Show member pathways Canonical NF-kB pathway ⁷⁴ Cellular Transformation by HTLV1 ⁶⁴ Inhibition of PKR ⁶⁶ STING pathway in Kawasaki-like disease and COVID-19 ⁷⁴	11.79	TNF IL1B IFNG
30	Calcineurin-regulated NFAT-dependent transcription in lymphocytes ⁶¹ Show member pathways Calcium signaling in the CD4+ TCR pathway ⁶¹	11.78	TNF IL5 IL4 IFNG
31	Burn wound healing ⁷⁴	11.76	TNF IL1B FLG
32	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.75	TNF IL1B IFNG
33	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.75	TNF IL1B IL1A IFNG
34	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.73	TNF IL5 IL4 IL1A IL13 IFNG
35	Th17 cell differentiation pathway ⁷⁴	11.72	IL4 IL1B IFNG
36	AP-1 transcription factor network ⁶¹	11.71	IL5 IL4 IFNG
37	IL 10 signaling pathway ⁶⁷	11.66	IL1A IL1B TNF
38	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	11.59	TNF IL1B IL1A IFNG
39	MSP-RON Signaling ⁶⁴	11.55	TNF IL1B IFNG
40	Interleukin-10 signaling ⁶⁶	11.55	CCL22 CXCL10 IL1A IL1B IL1RN TNF
41	Th2 Differentiation ⁶⁵	11.51	IL5 IL4 IL31 IL13 IFNG CCL22
42	Type II interferon signaling ⁷⁴	11.5	CXCL10 CXCL9 IFNG IL1B
43	2q13 copy number variation syndrome ⁷⁴	11.47	IL1RN IL1B IL1A
44	IL-10 Pathway ⁶⁴	11.4	TNF IL1B IL1A
45	Inflammatory response pathway ⁷⁴	11.37	IL5 IL4 IFNG
46	Prostaglandin signaling ⁷⁴	11.36	TNF IL1B IL1A CXCL9 CXCL10
47	OX40 Pathway ⁶⁴	11.33	IL5 IL4 IL13 IFNG
48	Immune infiltration in pancreatic cancer ⁷⁴	11.32	TNF IL5 IL4 IL13 IFNG
49	CXCR3-mediated signaling events ⁶¹	11.29	CXCL10 CXCL9 CXCR3
50	Development and heterogeneity of the ILC family ⁷⁴	11.2	TSLP TNF IL5 IL4 IL1B IL13

Sources

GO Terms for Contact Dermatitis

Cellular components related to Contact Dermatitis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	10.25	TSLP TNF IL5 IL4 IL31 IL1RN
2	external side of plasma membrane	GO:0009897	9.86	CCR4 CCR6 CXCL10 CXCL9 CXCR3 ICOSLG
3	extracellular space	GO:0005615	9.74	TSLP TNF IL5 IL4 IL31 IL1RN

Biological processes related to Contact Dermatitis according to GeneCards Suite gene sharing:

(show all 42)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	10.46	TNF IL4 IL1B IL1A IL13 IFNG
2	signal transduction	GO:0007165	10.27	CCL22 CCR4 CCR6 CXCL10 CXCL9 CXCR3
3	positive regulation of inflammatory response	GO:0050729	10.22	TSLP TNF IL1B IFNG
4	cellular response to lipopolysaccharide	GO:0071222	10.2	TNF IL1B IL1A CXCL9 CXCL10
5	response to virus	GO:0009615	10.19	TNF IFNG CXCL10 CCL22
6	calcium-mediated signaling	GO:0019722	10.19	TNF CXCR3 CCR6 CCR4
7	neutrophil chemotaxis	GO:0030593	10.18	IL1B CXCL9 CXCL10 CCL22
8	positive regulation of phagocytosis	GO:0050766	10.16	TNF IL1B IFNG
9	regulation of insulin secretion	GO:0050796	10.16	TNF IL1B IFNG
10	positive regulation of interleukin-6 production	GO:0032755	10.16	TSLP TNF IL1B IL1A IFNG
11	positive regulation of B cell proliferation	GO:0030890	10.15	IL5 IL4 IL13
12	chemotaxis	GO:0006935	10.15	CXCR3 CXCL9 CXCL10 CCR6 CCR4 CCL22
13	positive regulation of nitric oxide biosynthetic process	GO:0045429	10.14	TNF IL1B IFNG
14	positive regulation of interleukin-10 production	GO:0032733	10.14	TSLP IL4 IL13
15	defense response	GO:0006952	10.12	TNF ICOSLG CXCL9 CXCL10
16	negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	GO:2001240	10.11	IL1A IL1B TNF
17	extrinsic apoptotic signaling pathway in absence of ligand	GO:0097192	10.11	IL4 IL1B IL1A
18	cell chemotaxis	GO:0060326	10.11	CCL22 CCR4 CCR6 CXCR3
19	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	10.1	TSLP TNF IL4 IL13 IFNG
20	positive regulation of release of sequestered calcium ion into cytosol	GO:0051281	10.09	IL13 CXCL9 CXCL10
21	positive regulation of mitotic nuclear division	GO:0045840	10.09	TNF IL1B IL1A
22	positive regulation of cytokine production	GO:0001819	10.08	IFNG IL1A IL1B TNF
23	response to bacterium	GO:0009617	10.06	TNF CXCL9 CXCL10 CCR4
24	response to lipopolysaccharide	GO:0032496	10.05	TNF IL1B IL1A IL13 CXCL10
25	microglial cell activation	GO:0001774	10.03	IFNG IL13 IL4 TNF
26	chemokine-mediated signaling pathway	GO:0070098	10.03	CCL22 CCR4 CCR6 CXCL10 CXCL9 CXCR3
27	inflammatory response	GO:0006954	10.03	CCL22 CCR4 CXCL10 CXCL9 CXCR3 IL13
28	positive regulation of chemokine production	GO:0032722	10.02	TSLP TNF IL1B IFNG
29	positive regulation of membrane protein ectodomain proteolysis	GO:0051044	10	TNF IL1B IFNG
30	neuroinflammatory response	GO:0150076	9.98	IL4 IFNG
31	positive regulation of immature T cell proliferation in thymus	GO:0033092	9.97	IL1B IL1A
32	positive regulation of mononuclear cell migration	GO:0071677	9.97	IL4 TNF
33	astrocyte activation	GO:0048143	9.97	IFNG IL1B TNF
34	positive regulation of fever generation	GO:0031622	9.96	IL1B TNF
35	cellular response to interleukin-17	GO:0097398	9.95	IL1B CXCL10
36	sequestering of triglyceride	GO:0030730	9.93	TNF IL1B
37	fever generation	GO:0001660	9.91	IL1A IL1B
38	positive regulation of nitrogen compound metabolic process	GO:0051173	9.9	IFNG TNF
39	negative regulation of complement-dependent cytotoxicity	GO:1903660	9.89	IL13 IL4
40	positive regulation of vitamin D biosynthetic process	GO:0060557	9.86	TNF IFNG
41	positive regulation of calcidiol 1-monooxygenase activity	GO:0060559	9.8	TNF IL1B IFNG
42	immune response	GO:0006955	9.7	TNF IL5 IL4 IL1RN IL1B IL1A

Molecular functions related to Contact Dermatitis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	C-C chemokine binding	GO:0019957	9.85	CXCR3 CCR6 CCR4
2	C-C chemokine receptor activity	GO:0016493	9.73	CXCR3 CCR6 CCR4
3	CXCR3 chemokine receptor binding	GO:0048248	9.71	CXCL9 CXCL10
4	cytokine activity	GO:0005125	9.7	TSLP TNF IL5 IL4 IL31 IL1RN
5	chemokine receptor activity	GO:0004950	9.63	CXCR3 CCR6 CCR4
6	cytokine receptor binding	GO:0005126	9.62	IL4 IL31 IL13
7	interleukin-1 receptor binding	GO:0005149	9.35	IL1A IL1B IL1RN